| David Kabata Machungo, CRNA | |
|
2720 Sunset Blvd, West Columbia, SC 29169-4810 | |
| (803) 791-2000 | |
| Not Available |
| Full Name | David Kabata Machungo |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 19 Years |
| Location | 2720 Sunset Blvd, West Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225125735 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 4704239474 (Michigan) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 19486 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lexington Medical Center | West columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lexington Health Inc | 2567872070 | 753 |
| Consultants In Gastroenterology Pa | 2769527480 | 28 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Nearly two-thirds of the hospital in-patients who took part in a survey had experienced pain in the last 24 hours and 42% of those rated their pain as more than seven out of ten, where ten was the worst pain imaginable, according to the March issue of the Journal of Clinical Nursing.
Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
› Verified 3 days ago
| Entity Name | Consultants In Gastroenterology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326004839 PECOS PAC ID: 2769527480 Enrollment ID: O20100305000664 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Nearly two-thirds of the hospital in-patients who took part in a survey had experienced pain in the last 24 hours and 42% of those rated their pain as more than seven out of ten, where ten was the worst pain imaginable, according to the March issue of the Journal of Clinical Nursing.
Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
› Verified 3 days ago
| Entity Name | Sc Anesthesiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205109428 PECOS PAC ID: 1052573565 Enrollment ID: O20120430000408 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Nearly two-thirds of the hospital in-patients who took part in a survey had experienced pain in the last 24 hours and 42% of those rated their pain as more than seven out of ten, where ten was the worst pain imaginable, according to the March issue of the Journal of Clinical Nursing.
Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
› Verified 3 days ago
| Entity Name | Lexington Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710634753 PECOS PAC ID: 2567872070 Enrollment ID: O20201208000922 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Nearly two-thirds of the hospital in-patients who took part in a survey had experienced pain in the last 24 hours and 42% of those rated their pain as more than seven out of ten, where ten was the worst pain imaginable, according to the March issue of the Journal of Clinical Nursing.
Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Kabata Machungo, CRNA 45888 Winthrop Pl, Macomb, MI 48044-5790 Ph: () - | David Kabata Machungo, CRNA 2720 Sunset Blvd, West Columbia, SC 29169-4810 Ph: (803) 791-2000 |
News Archive
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
Nearly two-thirds of the hospital in-patients who took part in a survey had experienced pain in the last 24 hours and 42% of those rated their pain as more than seven out of ten, where ten was the worst pain imaginable, according to the March issue of the Journal of Clinical Nursing.
Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
› Verified 3 days ago
Caroline Marvin Bedingfield, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Aimee Yates Gondi, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2720 Sunset Blvd., West Columbia, SC 29169 Phone: 803-791-2000 | |
Mrs. Aimee Ahn Durgin, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Noreen Lyday Dudley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Jessica Leigh Rosebrock, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Holly J Jakubs, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Jennifer Lynn Dablock, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 |